Thomas Kramar

Chairman chez CARDEON AB Fortune : 20 865 $ au 31/03/2024

Profil

Thomas Kramar currently works at T M Kramar Group AB, as Chairman, Percy Falks Stiftelse, as Chairman, Cardeon AB, as Chairman, Typos, tiskarské závody, s.r.o., as Co-Managing Director from 2013, Lundonia Biotech AB, as Director from 2012, SpectraCure AB, as Director from 2022, Cytacoat AB, as Director, Gentian AS, as Director, and Corsmed AB, as Director from 2020.
Mr. Kramar also formerly worked at Siemens Healthcare AB, as Chief Executive Officer, Siemens Healthineers AG, as Chief Executive Officer, Cardeon AB (Old), as Chairman, Euro-Druckservice GmbH, as Managing Director, Nanologica AB, as Independent Director from 2020 to 2023, Gentian Diagnostics ASA, as Independent Director, and T M Kramar Group AB, as Manager-Global Business.
Mr. Kramar received his graduate degree from Faculty of Engineering, Lund University.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
GENTIAN DIAGNOSTICS ASA 0,04%	26/08/2022	5 802 ( 0,04% )	20 865 $	31/03/2024

Postes actifs de Thomas Kramar

Sociétés	Poste	Début
SPECTRACURE AB	Director/Board Member	01/01/2022
CARDEON AB	Chairman	-
Lundonia Biotech AB	Director/Board Member	-
Typos, tiskarské závody, s.r.o.	Chief Executive Officer	03/06/2013
Gentian AS	Director/Board Member	-
Cytacoat AB	Director/Board Member	-
Corsmed AB	Director/Board Member	01/05/2020
Percy Falks Stiftelse	Chairman	-
T M Kramar Group AB	Chairman	-

Anciens postes connus de Thomas Kramar

Sociétés	Poste	Fin
░░░░░░░░░░ ░░	░░░░░░░░░░░░░░ ░░░░░░	░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░ ░░	░░░░░ ░░░░░░░░░ ░░░░░░░	-
░░░░░░░ ░░░░░░░░░░░░ ░░	░░░░░ ░░░░░░░░░ ░░░░░░░	-
░░░░░░░░░░░░░░░░░ ░░░░	░░░░░ ░░░░░░░░░ ░░░░░░░	-
░░░░░░░ ░░░░░░░░░░░	░░░░░░░░░░░░░░ ░░░░░░	-

Formation de Thomas Kramar

Faculty of Engineering, Lund University

Graduate Degree